ASCT Tops CAR T-Cell Therapy for Relapsed LBCL in Complete Remission
Meeting Coverage > > ASH: Hematology-- Better 2-year PFS, OS, however not appropriate to main refractory illness
by Charles Bankhead, Senior Editor, MedPage Today December 10, 2023
SAN DIEGO-- Autologous stem-cell transplant (ASCT) resulted in enhanced results as compared to CAR T-cell treatment for clients with fallen back big B-cell lymphoma (LBCL) in total remission, a retrospective analysis revealed.
Clients who went through ASCT had less regressions at 2 years (27.8% vs 48.0%) and much better progression-free survival (PFS, 66.2% vs 47.8%), and general survival (OS, 78.9% vs 65.6%). In the subgroup of clients with early treatment failure, ASCT was connected wi...